Request Demo
Last update 18 Oct 2025
UCLM-802
Last update 18 Oct 2025
Overview
Basic Info
Drug Type Autologous CAR-T |
Synonyms UCLM 802, UCLM802 |
Target |
Action inhibitors |
Mechanism MSLN inhibitors(Mesothelin inhibitors), Immunologic cytotoxicity, T lymphocyte replacements |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhasePhase 1 |
First Approval Date- |
Regulation- |
Login to view timeline
Structure/Sequence
Sequence Code 41661CDR1-H
Sequence Code 23839830CDR2-L
Sequence Code 432636890CDR3-L
Sequence Code 1120202638CDR1-L
Sequence Code 1120202652CDR2-H
Sequence Code 1120202666CDR3-H
Sequence Code 1120202692VL
Sequence Code 1120202709VH
Sequence Code 1200587276
Related
2
Clinical Trials associated with UCLM-802NCT05783089
Anti-Mesothelin CAR-T Therapy in Subjects With Mesothelin-positive Advanced Malignant Solid Tumors.
NCT05775666
Exploratory Study to Evaluate the Safety, Tolerability and Preliminary Efficacy of UCLM802 (Anti-Mesothelin CAR-T) Cell Injection in Patients With Mesothelin-positive Advanced Malignant Solid Tumors
100 Clinical Results associated with UCLM-802
Login to view more data
100 Translational Medicine associated with UCLM-802
Login to view more data
100 Patents (Medical) associated with UCLM-802
Login to view more data
100 Deals associated with UCLM-802
Login to view more data
R&D Status
10 top R&D records. to view more data
Login
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Advanced Malignant Solid Neoplasm | Phase 1 | - | 01 Mar 2023 | |
| Biliary Tract Neoplasms | Phase 1 | - | 01 Mar 2023 | |
| Breast Cancer | Phase 1 | - | 01 Mar 2023 | |
| Endometrial Carcinoma | Phase 1 | - | 01 Mar 2023 | |
| Esophageal Carcinoma | Phase 1 | - | 01 Mar 2023 | |
| Intestinal Neoplasms | Phase 1 | - | 01 Mar 2023 | |
| Lung Cancer | Phase 1 | - | 01 Mar 2023 | |
| Mesothelin positive Solid Tumors | Phase 1 | - | 01 Mar 2023 | |
| Mesothelioma, Malignant | Phase 1 | - | 01 Mar 2023 | |
| Ovarian Cancer | Phase 1 | - | 01 Mar 2023 |
Login to view more data
Clinical Result
Clinical Result
Indication
Phase
Evaluation
View All Results
Login to view more data
Translational Medicine
Boost your research with our translational medicine data.
login
or
Deal
Boost your decision using our deal data.
login
or
Core Patent
Boost your research with our Core Patent data.
login
or
Clinical Trial
Identify the latest clinical trials across global registries.
login
or
Approval
Accelerate your research with the latest regulatory approval information.
login
or
Regulation
Understand key drug designations in just a few clicks with Synapse.
login
or
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free